ObsEva SA (OBSV) is a clinical-stage biopharmaceutical company that is focused on developing and commercializing novel therapeutics for women's reproductive health and pregnancy-related disorders. The company's lead product candidate, linzagolix, is an orally administered gonadotropin-releasing hormone receptor antagonist that is being developed for the treatment of uterine fibroids and endometriosis. ObsEva is also developing a pipeline of other product candidates, including nolasiban, which is being developed for the improvement of pregnancy and live birth rates in women undergoing in vitro fertilization.
ObsEva was founded in 2012 and is headquartered in Geneva, Switzerland. The company is listed on the NASDAQ stock exchange.
ObsEva SA (OBSV) is a clinical-stage biopharmaceutical company that is focused on developing and commercializing novel therapeutics for women's reproductive health and pregnancy-related disorders. The company's lead product candidate, linzagolix, is an orally administered gonadotropin-releasing hormone receptor antagonist that is being developed for the treatment of uterine fibroids and endometriosis. ObsEva is also developing a pipeline of other product candidates, including nolasiban, which is being developed for the improvement of pregnancy and live birth rates in women undergoing in vitro fertilization.